FLGT Oct 2024 22.500 call
| Previous close | 2.6800 |
| Open | 2.7000 |
| Bid | 2.4000 |
| Ask | 2.9000 |
| Strike | 22.50 |
| Expiry date | 2024-10-18 |
| Day's range | 2.6800 - 2.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 37 |
Business WireMoffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
TAMPA, Fla. & LOS ANGELES, May 14, 2024--Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, announced today a strategic partnership aimed at advancing cancer treatment through clinical development and pre-clinical co-development initiatives. This collaboration combines Moffitt’s cutting-edge clinical capabilit
Simply Wall St.Fulgent Genetics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Fulgent Genetics ( NASDAQ:FLGT ) First Quarter 2024 Results Key Financial Results Revenue: US$64.5m (down 2.5% from 1Q...
Insider MonkeyFulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2024 Earnings Call Transcript
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2024 Earnings Call Transcript May 3, 2024 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.33. Fulgent Genetics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to […]
